- Home
- CDLX vs FENC Comparison
CDLX vs FENC Comparison
Compare CDLX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLX
- FENC
- Stock Information
- Founded
- CDLX 2008
- FENC 1996
- Country
- CDLX United States
- FENC United States
- Employees
- CDLX N/A
- FENC N/A
- Industry
- CDLX Computer Software: Programming Data Processing
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDLX Technology
- FENC Health Care
- Exchange
- CDLX Nasdaq
- FENC Nasdaq
- Market Cap
- CDLX 180.4M
- FENC 156.9M
- IPO Year
- CDLX 2018
- FENC 2001
- Fundamental
- Price
- CDLX $2.98
- FENC $6.65
- Analyst Decision
- CDLX Hold
- FENC Strong Buy
- Analyst Count
- CDLX 6
- FENC 2
- Target Price
- CDLX $5.90
- FENC $14.00
- AVG Volume (30 Days)
- CDLX 979.5K
- FENC 58.2K
- Earning Date
- CDLX 03-13-2025
- FENC 03-20-2025
- Dividend Yield
- CDLX N/A
- FENC N/A
- EPS Growth
- CDLX N/A
- FENC N/A
- EPS
- CDLX N/A
- FENC N/A
- Revenue
- CDLX $293,468,000.00
- FENC $49,348,000.00
- Revenue This Year
- CDLX N/A
- FENC $170.43
- Revenue Next Year
- CDLX $3.49
- FENC $6.70
- P/E Ratio
- CDLX N/A
- FENC N/A
- Revenue Growth
- CDLX N/A
- FENC 278.09
- 52 Week Low
- CDLX $2.76
- FENC $3.96
- 52 Week High
- CDLX $20.52
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- CDLX 36.80
- FENC 66.40
- Support Level
- CDLX $2.76
- FENC $6.30
- Resistance Level
- CDLX $4.05
- FENC $6.64
- Average True Range (ATR)
- CDLX 0.26
- FENC 0.29
- MACD
- CDLX -0.04
- FENC 0.06
- Stochastic Oscillator
- CDLX 10.69
- FENC 90.23
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.